Comparing mismatch strategies for patients being considered for ischemic stroke tenecteplase trials
نویسندگان
چکیده
منابع مشابه
The Effect of Diagnostic Catheter Angiography on Outcomes of Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment.
BACKGROUND The risk of catheter-based angiograms alone (non-therapeutic angiogram that does not lead to therapeutic intervention) in acute ischemic stroke patients who are considered for endovascular treatment is not well studied. METHODS We compared the rates of neurological deterioration within 24 h; symptomatic intracranial hemorrhage (ICH) within 30 h; acute kidney injury (AKI) and major ...
متن کاملThrombolysis for acute ischemic stroke by tenecteplase in the emergency department of a Moroccan hospital
INTRODUCTION Thrombolysis has radically changed the prognosis of acute ischemic stroke. Tenecteplase is a modified form of rt-PA with greater specificity for fibrin and a longer half-life. We report the experience of a Moroccan tertiary hospital in thrombolysis using Tenecteplase. METHODS We conducted an open prospective study of all patients who were treated with Tenecteplase for an acute is...
متن کاملAutoresuscitation after asystole in patients being considered for organ donation.
OBJECTIVES A fundamental issue in organ donation after circulatory death is the determination of death. There are limited data regarding the incidence and timing of autoresuscitation after asystole. Prevailing guidelines suggest a 2- to 5-min observation after mechanical asystole before the declaration of death. This study tested the hypothesis that a 2-min observation period after asystole is ...
متن کاملTrials of Trials in Acute Ischemic Stroke
Afew years ago, a distinguished colleague and expert in stroke told me, "When we have a treatment for stroke, we will know it" (R. Siekert, personal communication). I agree with this insightful comment, but I also wonder how we will know. Because stroke is a very complex condition with a number of clinical variables that compound care and influence outcome, it is unlikely that any therapy will ...
متن کاملA randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS In this phase 2B trial, we randomly assigned 75 patients to receive alteplase (0.9 mg per kilogram of body weight) or tenecteplase (0.1 mg per kilogram or 0.25 mg per kilogram) less ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Stroke
سال: 2019
ISSN: 1747-4930,1747-4949
DOI: 10.1177/1747493019884529